Loading
collectionsCollection
ESMO Clinical Practice Guidelines & MCBS
The ESMO guidelines are Europe's treatment algorithms, and the ESMO-MCBS scores how much each new drug actually helps.
Overview
The ESMO Clinical Practice Guidelines are Europe's treatment algorithms, and the accompanying ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) scores how much each new drug actually helps. ESMO-MCBS grades trials A to C in the curative setting and 1 to 5 in the non-curative setting according to the magnitude of benefit. Both are maintained by the European Society for Medical Oncology (ESMO) and are free to read. On OnCo the collection is cited by the bottlenecks Trial design, endpoints and cost, Regulatory divergence between regions, Prices and value, Incentives reward me-too drugs and marginal gains and Toxicity and quality of life are undervalued, and by ideas such as Guidelines list the open trials at every decision point, updated monthly.
Holds
European treatment guidelines and the Magnitude of Clinical Benefit Scale.
Licence
Free
Maintainer
ESMO
guidelineAnnals of Oncology 2024changed practice700 citations
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This is the European standard the UK page for triple-negative breast cancer is compared against; NICE guidance covers the same ground with a narrower set of funded drugs.
guidelineAnnals of Oncology 2023changed practice507 citations
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This is the reference European standard against which UK and NHS practice for gallbladder cancer is compared; it treats gallbladder cancer within biliary tract cancer rather than as its own disease.
guidelineAnnals of Oncology 2023changed practice1,512 citations
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This is the European standard the UK and NHS page for colorectal cancer is compared against; NICE NG151 covers the same ground for England with a narrower set of funded drugs.
guidelineAnnals of Oncology 2023changed practice426 citations
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.
guidelineAnnals of Oncology 2021changed practice1,204 citations
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
The document that made immunotherapy, PARP inhibition and the first antibody-drug conjugate the European standard for metastatic triple-negative disease; every later first-line change is an amendment to it.
guidelineAnnals of Oncology 2020changed practice1,014 citations
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
The European rulebook for what happens after a colon cancer operation, and the reason a patient with a T3 N1 tumour is now offered three months of chemotherapy rather than six.
guidelineAnnals of Oncology 2017changed practice1,445 citations
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
The document behind the MRI-first rectal cancer pathway used across Europe and the UK; the total neoadjuvant therapy trials (RAPIDO, PRODIGE 23, OPRA) that came after it are the main reason an update was needed.
Similar pages
- CollectionNCCN Guidelines
Shares Alert guidelines and trials when a paper they rely on is retracted, Guidelines list the open trials at every decision point, updated monthly, ASCO clinical practice guidelines, A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer.
- PersonAndrés Cervantes
Shares Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, European Society for Medical Oncology (ESMO).
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Incentives reward me-too drugs and marginal gains, Prices and value.
- Key paperUpdated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline
Shares ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, European Society for Medical Oncology (ESMO), Annals of Oncology.
- IdeaTie coverage and copays to the ESMO benefit scale
Shares European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly, Incentives reward me-too drugs and marginal gains, Prices and value.
- InstitutionNational Comprehensive Cancer Network (NCCN)
Shares Living guidelines published as versioned, computable rules, Knowledge reaches practice too slowly, Fragmented care and guideline gaps, Prices and value.
- TermStandard of care
Shares ASCO clinical practice guidelines, Knowledge reaches practice too slowly, Incentives reward me-too drugs and marginal gains, Regulatory divergence between regions.
- InstitutionAmerican Society of Clinical Oncology (ASCO)
Shares ASCO clinical practice guidelines, A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer, Living guidelines published as versioned, computable rules, Weak real-world evidence and registries.
institutions
roadmaps
ideas
A cheap old tablet to restore appetiteA fixed share of trial-group funding for getting proven care to patientsA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturerAlert guidelines and trials when a paper they rely on is retractedGuidelines list the open trials at every decision point, updated monthlyLabel every biomarker claim with an evidence phase, like drugsLive guideline-concordance dashboards for every tumour board, generated from the recordLiving guidelines published as versioned, computable rules
collections
bottlenecks
key papers
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEarly breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerLocalised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upMetastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up